Tekla Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-77,061
| Closed | -$92K | – | 218 |
|
|
2019
Q4 | $92K | Hold |
77,061
| – | – | ﹤0.01% | 211 |
|
|
2019
Q3 | $116K | Sell |
77,061
-151,435
| -66% | -$228K | 0.01% | 187 |
|
|
2019
Q2 | $919K | Hold |
228,496
| – | – | 0.04% | 168 |
|
|
2019
Q1 | $983K | Hold |
228,496
| – | – | 0.04% | 163 |
|
|
2018
Q4 | $1.31M | Sell |
228,496
-123,122
| -35% | -$708K | 0.06% | 149 |
|
|
2018
Q3 | $4.77M | Sell |
351,618
-503,850
| -59% | -$6.83M | 0.17% | 95 |
|
|
2018
Q2 | $10.2M | Hold |
855,468
| – | – | 0.39% | 60 |
|
|
2018
Q1 | $9.61M | Sell |
855,468
-79,900
| -9% | -$897K | 0.37% | 58 |
|
|
2017
Q4 | $6.25M | Hold |
935,368
| – | – | 0.24% | 78 |
|
|
2017
Q3 | $7.66M | Sell |
935,368
-531,000
| -36% | -$4.35M | 0.27% | 69 |
|
|
2017
Q2 | $6.58M | Hold |
1,466,368
| – | – | 0.24% | 77 |
|
|
2017
Q1 | $8.08M | Buy |
1,466,368
+900,000
| +159% | +$4.96M | 0.31% | 65 |
|
|
2016
Q4 | $2.29M | Hold |
566,368
| – | – | 0.1% | 101 |
|
|
2016
Q3 | $3.99M | Buy |
566,368
+269,434
| +91% | +$1.9M | 0.15% | 92 |
|
|
2016
Q2 | $2.42M | Hold |
296,934
| – | – | 0.1% | 109 |
|
|
2016
Q1 | $2.41M | Hold |
296,934
| – | – | 0.1% | 110 |
|
|
2015
Q4 | $3.58M | Buy |
296,934
+15,000
| +5% | +$181K | 0.13% | 101 |
|
|
2015
Q3 | $3.38M | Buy |
281,934
+254,434
| +925% | +$3.05M | 0.12% | 102 |
|
|
2015
Q2 | $504K | Buy |
+27,500
| New | +$504K | 0.02% | 102 |
|